An update of pharmacoeconomic analysis of trastuzumab emtanzine in patients with HER2+ breast cancer and central nervous system metastases
Introduction. Regardless the pharmacoeconomic evaluation of trastuzumab emtanzine (T-DM-1) has been done before new data concerning T-DM1 effectiveness and also costs data require an update of pharmacoeconomic evaluation. Aim. To update pharmacoeconomic evaluation of T-DM1 in patients with HER2+ bre...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Izdatelstvo OKI
2019-04-01
|
| Series: | Качественная клиническая практика |
| Subjects: | |
| Online Access: | https://www.clinvest.ru/jour/article/view/424 |
| _version_ | 1797262057755639808 |
|---|---|
| author | A. S. Kolbin A. A. Kurylev Y. E. Balykina M. A. Proskurin |
| author_facet | A. S. Kolbin A. A. Kurylev Y. E. Balykina M. A. Proskurin |
| author_sort | A. S. Kolbin |
| collection | DOAJ |
| description | Introduction. Regardless the pharmacoeconomic evaluation of trastuzumab emtanzine (T-DM-1) has been done before new data concerning T-DM1 effectiveness and also costs data require an update of pharmacoeconomic evaluation. Aim. To update pharmacoeconomic evaluation of T-DM1 in patients with HER2+ breast cancer (BC) and CNS metastases. Materials and methods. Cost-effectiveness analysis along with sensitivity analysis were performed. Direct medical costs and indirect costs (GDP loss) were accounted. Results. At 5 years modeling horizon total cost of trastuzumab emtanzine were higher comparing to lapatinib+capecitabine due to significantly higher overall survival (OS) observed in T-DM1 group. CER OS for T-DM1 was by 21% lower comparing to CER lapatinib+capecitabine (2 099 940 RUR/patient/year and 2 541 879 RUR/patient/year, consequently). Conclusions. The study showed T-DM1 is a cost-effective strategy in patient with HER2+ metastatic BC and CNS metastases. |
| first_indexed | 2024-04-24T23:51:04Z |
| format | Article |
| id | doaj.art-a7d431101f2f4a82baca414205d7acd9 |
| institution | Directory Open Access Journal |
| issn | 2588-0519 2618-8473 |
| language | Russian |
| last_indexed | 2024-04-24T23:51:04Z |
| publishDate | 2019-04-01 |
| publisher | Izdatelstvo OKI |
| record_format | Article |
| series | Качественная клиническая практика |
| spelling | doaj.art-a7d431101f2f4a82baca414205d7acd92024-03-14T18:09:08ZrusIzdatelstvo OKIКачественная клиническая практика2588-05192618-84732019-04-0104253210.24411/2588-0519-2018-10056424An update of pharmacoeconomic analysis of trastuzumab emtanzine in patients with HER2+ breast cancer and central nervous system metastasesA. S. Kolbin0A. A. Kurylev1Y. E. Balykina2M. A. Proskurin3Первый Санкт-Петербургский государственный медицинский университет им. академика И.П. Павлова; Санкт-Петербургский государственный университетСанкт-Петербургский государственный университетСанкт-Петербургский государственный университетСанкт-Петербургский государственный университетIntroduction. Regardless the pharmacoeconomic evaluation of trastuzumab emtanzine (T-DM-1) has been done before new data concerning T-DM1 effectiveness and also costs data require an update of pharmacoeconomic evaluation. Aim. To update pharmacoeconomic evaluation of T-DM1 in patients with HER2+ breast cancer (BC) and CNS metastases. Materials and methods. Cost-effectiveness analysis along with sensitivity analysis were performed. Direct medical costs and indirect costs (GDP loss) were accounted. Results. At 5 years modeling horizon total cost of trastuzumab emtanzine were higher comparing to lapatinib+capecitabine due to significantly higher overall survival (OS) observed in T-DM1 group. CER OS for T-DM1 was by 21% lower comparing to CER lapatinib+capecitabine (2 099 940 RUR/patient/year and 2 541 879 RUR/patient/year, consequently). Conclusions. The study showed T-DM1 is a cost-effective strategy in patient with HER2+ metastatic BC and CNS metastases.https://www.clinvest.ru/jour/article/view/424рак молочной железытрастузумаб эмтазинанализ затраты—эффективностьфармакоэкономикаанализ влияния на бюджет |
| spellingShingle | A. S. Kolbin A. A. Kurylev Y. E. Balykina M. A. Proskurin An update of pharmacoeconomic analysis of trastuzumab emtanzine in patients with HER2+ breast cancer and central nervous system metastases Качественная клиническая практика рак молочной железы трастузумаб эмтазин анализ затраты—эффективность фармакоэкономика анализ влияния на бюджет |
| title | An update of pharmacoeconomic analysis of trastuzumab emtanzine in patients with HER2+ breast cancer and central nervous system metastases |
| title_full | An update of pharmacoeconomic analysis of trastuzumab emtanzine in patients with HER2+ breast cancer and central nervous system metastases |
| title_fullStr | An update of pharmacoeconomic analysis of trastuzumab emtanzine in patients with HER2+ breast cancer and central nervous system metastases |
| title_full_unstemmed | An update of pharmacoeconomic analysis of trastuzumab emtanzine in patients with HER2+ breast cancer and central nervous system metastases |
| title_short | An update of pharmacoeconomic analysis of trastuzumab emtanzine in patients with HER2+ breast cancer and central nervous system metastases |
| title_sort | update of pharmacoeconomic analysis of trastuzumab emtanzine in patients with her2 breast cancer and central nervous system metastases |
| topic | рак молочной железы трастузумаб эмтазин анализ затраты—эффективность фармакоэкономика анализ влияния на бюджет |
| url | https://www.clinvest.ru/jour/article/view/424 |
| work_keys_str_mv | AT askolbin anupdateofpharmacoeconomicanalysisoftrastuzumabemtanzineinpatientswithher2breastcancerandcentralnervoussystemmetastases AT aakurylev anupdateofpharmacoeconomicanalysisoftrastuzumabemtanzineinpatientswithher2breastcancerandcentralnervoussystemmetastases AT yebalykina anupdateofpharmacoeconomicanalysisoftrastuzumabemtanzineinpatientswithher2breastcancerandcentralnervoussystemmetastases AT maproskurin anupdateofpharmacoeconomicanalysisoftrastuzumabemtanzineinpatientswithher2breastcancerandcentralnervoussystemmetastases AT askolbin updateofpharmacoeconomicanalysisoftrastuzumabemtanzineinpatientswithher2breastcancerandcentralnervoussystemmetastases AT aakurylev updateofpharmacoeconomicanalysisoftrastuzumabemtanzineinpatientswithher2breastcancerandcentralnervoussystemmetastases AT yebalykina updateofpharmacoeconomicanalysisoftrastuzumabemtanzineinpatientswithher2breastcancerandcentralnervoussystemmetastases AT maproskurin updateofpharmacoeconomicanalysisoftrastuzumabemtanzineinpatientswithher2breastcancerandcentralnervoussystemmetastases |